Simplify Logo

Full-Time

Senior Process Development Scientist

Molecular Biology

Confirmed live in the last 24 hours

Elegen

Elegen

51-200 employees

Custom DNA synthesis for biotech applications

Biotechnology
Healthcare

Compensation Overview

$140k - $170kAnnually

+ Bonus + Equity + Benefits

Senior, Expert

San Carlos, CA, USA

Category
Bioinformatics
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Python
R
Git
Data Analysis
Requirements
  • PhD in the life sciences one, with 5+ years of hands-on molecular biology experience in assay, product, and/or process development.
  • High proficiency in applied statistics, and understanding of fundamental concepts in statistical analysis.
  • Experience developing molecular biology/biochemistry assays from conception through data analysis.
  • Previous experience with process modeling and implementation of process improvements.
  • Programming experience (R/Python/other, GitHub links if available) for developing custom modeling capabilities.
  • Experience with nucleic acid purification, quantification and qualification, molecular cloning, PCR, and NGS sequencing.
  • Excellent written and verbal communication skills.
Responsibilities
  • Study and analyze processes as designed, model process behaviors, and help identify key metrics.
  • Translate bench scale methods into an automatable form.
  • Analyze large data sets to improve process steps (efficiency, cost and throughput) and product (quality, yield, format).
  • Help identify major areas of improvement and provide framework (ranges, metrics, requirements) for new process designs, outline/design experiments for this purpose.
  • Clearly communicate findings to the core team, and other functional teams in the organization.
  • Collaborate in process transfer for commercial scale manufacturing, partner with the Production, Automation and Software teams to troubleshoot process and method, rigorously monitor processes post transfer for a limited number of runs.

Elegen focuses on improving the process of manufacturing synthetic DNA to meet the needs of the bioeconomy. The company provides custom DNA synthesis services to researchers, biotech companies, and pharmaceutical firms that require high-quality synthetic DNA for various applications, including biomanufacturing and mRNA-based treatments. Elegen's services are characterized by fast turnaround times and high accuracy, which are essential for clients' research and development. Unlike traditional DNA manufacturing methods, Elegen's approach reduces time and costs while enabling the production of valuable biologics and therapeutics. The company's goal is to support advancements in synthetic biology and biomanufacturing, particularly in the development of mRNA medicines and other advanced therapeutics.

Company Stage

Seed

Total Funding

$42.9M

Headquarters

San Carlos, California

Founded

2017

Growth & Insights
Headcount

6 month growth

14%

1 year growth

32%

2 year growth

114%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $35M Series B funding, led by prominent investors like Triatomic Capital and GSK, will accelerate the expansion of Elegen’s ENFINIA™ DNA product line and enhance its clinical manufacturing capabilities.
  • Elegen's collaboration and licensing agreement with GSK to use their proprietary cell-free DNA manufacturing technology in developing vaccines and medicines highlights the company's potential for significant industry impact.
  • The commercial launch of the enhanced ENFINIA™ DNA, which offers highly complex DNA in as fast as 10 business days, positions Elegen as a leader in rapid and reliable DNA synthesis.

What critics are saying

  • The synthetic biology market is highly competitive, requiring Elegen to continuously innovate to maintain its edge.
  • Dependence on key partnerships, such as with GSK, could pose risks if these relationships were to change or dissolve.

What makes Elegen unique

  • Elegen's cell-free DNA manufacturing technology offers a significant advantage over traditional plasmid-based methods, reducing contamination risks and accelerating production timelines.
  • The company's ENFINIA™ DNA product line provides highly complex, NGS-verified DNA with rapid turnaround times, setting a new industry standard.
  • Elegen's Early Access Program fosters strong client relationships and provides an additional revenue stream by offering early access to their latest DNA breakthroughs.